We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Adamas Provides Positive Long-term Data on Parkinson's Drug
Read MoreHide Full Article
Adamas Pharmaceuticals, Inc. presented expanded analysis from an ongoing open label phase III study – EASE LID 2 – on its lead candidate, ADS-5102 extended-release capsules. The candidate is being evaluated for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease (PD).
We note that a new drug application supporting ADS-5102 for the treatment of LID in patients suffering from Parkinson’s disease is already under review in the U.S. with a FDA decision expected on Aug 24, 2017.
The open label study evaluated ADS-5102, administered once daily at bedtime, in patients who were treated with amantadine immediate-release (IR) in three different clinical studies and patients who have undergone prior deep brain stimulation (DBS) treatment.
Data from the study demonstrated maintenance of a reduced and nearly constant level of dyskinesia and OFF at 88 weeks in patients receiving ADS-5102, as assessed by the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), Part IV score. The candidate was generally well tolerated. The study met its primary endpoint and supported the long-term safety and tolerability of ADS-5102. The data were presented at the International Congress of Parkinson’s Disease and Movement Disorders in Vancouver, Canada.
So far this year, Adamas’ share price has outperformed the Zacks categorized Medical-Generic Drugs industry. The stock gained 2.9% against a decrease of 5.5% for the broader industry.
Moreover, the data showed significant reduction in MDS-UPDRS Part IV at Week 8 in patients who underwent prior amantadine IR treatment and a comparable reduction in patients with DBS treatment.
As per the company’s press release, there are about one million people in the U.S. affected by Parkinson’s disease. These patients are treated with Levodopa, which is the standard of care for the disease. However, as the disease progresses, the majority of the patients, estimated to be 150,000 to 200,000 in the U.S, experience LID.
ADS-5102 is also being developed for walking impairment in people with multiple sclerosis. The company’s pipeline also includes ADS-4101 (lacosamide) for the treatment of partial onset seizures in epilepsy, which is a modified version of UCB SA’s (UCBJF - Free Report) Vimpat.
VIVUS’ loss per share estimates narrowed from 50 cents to 39 cents for 2017 over the last 60 days. The company posted positive earnings surprises in all the four trailing quarters, with an average beat of 233.69%.
Zoetis’ earnings per share estimates increased from $2.32 to $2.34 for 2017 over the last 60 days. The company posted positive earnings surprises in all the four trailing quarters, with an average beat of 9.82%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020. Click here for the 6 trades >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Adamas Provides Positive Long-term Data on Parkinson's Drug
Adamas Pharmaceuticals, Inc. presented expanded analysis from an ongoing open label phase III study – EASE LID 2 – on its lead candidate, ADS-5102 extended-release capsules. The candidate is being evaluated for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease (PD).
We note that a new drug application supporting ADS-5102 for the treatment of LID in patients suffering from Parkinson’s disease is already under review in the U.S. with a FDA decision expected on Aug 24, 2017.
The open label study evaluated ADS-5102, administered once daily at bedtime, in patients who were treated with amantadine immediate-release (IR) in three different clinical studies and patients who have undergone prior deep brain stimulation (DBS) treatment.
Data from the study demonstrated maintenance of a reduced and nearly constant level of dyskinesia and OFF at 88 weeks in patients receiving ADS-5102, as assessed by the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), Part IV score. The candidate was generally well tolerated. The study met its primary endpoint and supported the long-term safety and tolerability of ADS-5102. The data were presented at the International Congress of Parkinson’s Disease and Movement Disorders in Vancouver, Canada.
So far this year, Adamas’ share price has outperformed the Zacks categorized Medical-Generic Drugs industry. The stock gained 2.9% against a decrease of 5.5% for the broader industry.
Moreover, the data showed significant reduction in MDS-UPDRS Part IV at Week 8 in patients who underwent prior amantadine IR treatment and a comparable reduction in patients with DBS treatment.
As per the company’s press release, there are about one million people in the U.S. affected by Parkinson’s disease. These patients are treated with Levodopa, which is the standard of care for the disease. However, as the disease progresses, the majority of the patients, estimated to be 150,000 to 200,000 in the U.S, experience LID.
ADS-5102 is also being developed for walking impairment in people with multiple sclerosis. The company’s pipeline also includes ADS-4101 (lacosamide) for the treatment of partial onset seizures in epilepsy, which is a modified version of UCB SA’s (UCBJF - Free Report) Vimpat.
Adamas Pharmaceuticals, Inc. Price
Adamas Pharmaceuticals, Inc. Price | Adamas Pharmaceuticals, Inc. Quote
Zacks Rank & Stocks to Consider
Adamas Pharma currently has a Zacks Rank #4 (Sell).
A couple of better-ranked stocks in the health care sector include VIVUS, Inc. , sporting a Zacks Rank #1 (Strong Buy),and Zoetis Inc. (ZTS - Free Report) , carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks Rank #1 stocks here.
VIVUS’ loss per share estimates narrowed from 50 cents to 39 cents for 2017 over the last 60 days. The company posted positive earnings surprises in all the four trailing quarters, with an average beat of 233.69%.
Zoetis’ earnings per share estimates increased from $2.32 to $2.34 for 2017 over the last 60 days. The company posted positive earnings surprises in all the four trailing quarters, with an average beat of 9.82%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020. Click here for the 6 trades >>